Physician profile
Lorie Loreman
NPI 1285612291
$62,414.27
in general payments reported to CMS, 2019-2025
43 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $11K · 2021: $1,165 · 2022: $5,582 · 2023: $25K · 2024: $1,460 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $4,559 · Consulting Fee: $1,232 · Education: $23.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,425.00 |
| Food and Beverage | $4,559.41 |
| Consulting Fee | $1,232.00 |
| Education | $23.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29,075.51 | 2019-2025 | Trelegy Ellipta, Nucala |
| Mylan Specialty L.P. | $10,760.69 | 2019-2024 | Yupelri |
| Genzyme Corporation | $6,461.55 | 2019-2025 | |
| Insmed, INC. | $5,227.12 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $4,860.55 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $1,738.38 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,451.55 | 2019-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $356.84 | 2021-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $222.44 | 2020-2024 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $214.02 | 2020 | |
| Intuitive Surgical, INC. | $197.82 | 2022-2025 | |
| Inari Medical, INC. | $193.45 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Verona Pharma, INC. | $165.89 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $142.43 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Mayne Pharma Commercial LLC | $128.64 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorie Loreman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.